Mylan Laboratories Inc. has announced that the U.S. Court of Appeals for the Federal Circuit upheld a district court decision that Mylan's Oxybutynin products do not infringe a patent for DITROPAN XL an
SemBioSys Genetics has announced it has been granted U.S. patent 7,098,383 entitled "Methods for the production of multimeric immunoglobulins, and related compositions". The claims of the pat
ExonHit Therapeutics S.A., a drug and diagnostic discovery company, has announced that Merck & Co., Inc. has been granted a non-exclusive license to rights for research only under Patent US 6,881,
The Administrative Law Judge at the U.S. International Trade Commission (ITC) issued his Initial Determination concluding that Acambis plc's smallpox vaccine product (MVA3000) infringes two of Bava
Pfizer said today that the District Court of The Hague in the Netherlands has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor p
Ranbaxy Laboratories Limited (Ranbaxy) has announced that The District Court of The Hague has handed down a decision in Ranbaxy's case against (Pfizer) Warner-Lambert over the cholesterol-lowering dru
Court cases regarding patent infringement effectively slow generics in coming to market, however US lawmakers and FDA continue to make it easier for generic drugs to gain approval (Cutting Edge In
Researchers at Virginia Commonwealth University Medical Center have developed and patented a new, noninvasive means of measuring blood pressure inside the heart. The measurement to determine centr
SpectraScience has announced that it has filed for a new patent with the United States Patent and Trademark Office. The application is titled "System and Method for Non-Endoscopic Optica
NanoMed Pharmaceuticals has announced that founders Russell J. Mumper, Ph.D. and Michael Jay, Ph.D. have been issued U.S. Patent 7,153,525 entitled "Microemulsions As Precursors To Solid Nanoparti
The patent relates to novel compounds that modulate the 5-HT2C serotonin receptor, which helps regulate food intake and may also influence metabolic rate. These modulators could be useful in pharmaceutical compositions for the treatment of obesity. APD356, discovered by Arena, is a selective and orally available 5-HT2C receptor modulator covered by the patent. A 12-week, randomized, double-blind, dose-ranging Phase 2b clinical trial studying APD356 in obese patients is currently ongoing.
"This patent, along with a similar patent granted by the European Patent Office earlier this year, provides important protection for our lead drug candidate, APD356," commented Jack Lief, Arena's President and Chief Executive Officer. "We are looking forward to announcing top-line, longer term safety and efficacy data from our Phase 2b clinical trial of APD356 around the end of the year."
APD356 stimulates the 5-HT2C serotonin receptor, a G protein-coupled receptor located in the part of the brain called the hypothalamus, which helps regulate food intake and may also influence metabolic rate. APD356 has approximately 100-fold selectivity in vitro for the 5-HT2C receptor relative to the 5-HT2B receptor. Arena believes the 5-HT2B receptor is primarily implicated in the cardiac valvulopathy observed with non-selective serotonergic agents. In addition, APD356 has approximately 15-fold selectivity in vitro for the 5-HT2C receptor versus the 5-HT2A receptor, a central nervous system (CNS) receptor thought to be responsible for many of the CNS adverse effects of non-selective serotonergic agents. Arena believes that the selectivity of APD356 for the 5-HT2C receptor will allow the compound to be dosed at a well-tolerated level that will induce clinically relevant weight loss without the side effects observed with non-selective serotonergic agents.
http://www.arenapharm.com/